BIO 2019 Notebook: Merck On Finding The Right Balance, NORD On Patient Engagement, Sandoz On The Next Wave Of Biosimilars

 
• By Joseph Haas and Sue Sutter

News and views from day three of the BIO International Convention: Merck’s Frazier champions both social justice and capitalism; National Organization for Rare Disorders’ Salstonstall sees impact from FDA reviewers talking to patients; Sandoz’s Pike thinks refinement of clinical data requirements will encourage biosimilar sponsors to target more moderate-selling biologics.

Bio 2019 Notebook for Pink
FDA is helping NORD obtain funding for longitudinal natural history studies of rare diseases that lack approved drug therapy.

More from Biosimilars

More from Biosimilars & Generics